New Studies | Surviving Mesothelioma

Compound in Broccoli May Enhance Mesothelioma Treatment with Cisplatin

There is new evidence that a compound found in cruciferous vegetables like broccoli and cabbage may enhance the anticancer benefits of the platinum-based drug cisplatin in the treatment of pleural mesothelioma. Although malignant mesothelioma is highly resistant to conventional cancer treatments, most mesothelioma patients will receive chemotherapy with cisplatin and pemetrexed (Alimta) as part of a multi-modal approach to treatment. Now, researchers Yoon-Jin and Sang-Han … Continue reading Compound in Broccoli May Enhance Mesothelioma Treatment with Cisplatin »

Mesothelioma Risk Continues to Rise for Decades After Asbestos Exposure

Pleural Mesothelioma Incidence

A pair of Polish researchers have confirmed what a number of other studies have suggested – that the risk of contracting malignant mesothelioma continues to rise, even decades after a person’s last exposure to asbestos. The study was conducted by asbestos-exposure experts at the Nofer Institute of Occupational Medicine and included a total of 131 patients with pleural mesothelioma. Another 655 people enrolled in a … Continue reading Mesothelioma Risk Continues to Rise for Decades After Asbestos Exposure »

The Influence of BAP1 on Mesothelioma Survival

A mutation on the BAP1 tumor suppressor gene can influence the development of malignant mesothelioma but may have little bearing on survival. That conclusion comes from a new Chinese study of more than 2,400 people with cancers directly linked to the BAP1 genetic mutation, including pleural mesothelioma. BAP1 and Mesothelioma BRCA1-associated protein 1 (BAP1) is a tumor suppressing protein encoded by the BAP1 gene. Multiple studies … Continue reading The Influence of BAP1 on Mesothelioma Survival »

Boosting Mesothelioma Survival with VEGF-Inhibitor

The VEGF inhibitor cediranib may not yet be out of the running as a mesothelioma treatment. Although previous studies have found it to have dose-limiting side effects, a new study in the Journal of Thoracic Oncology finds that, at the right dose, it could boost the effectiveness of standard mesothelioma chemotherapy. What is Cediranib? Cediranib, an oral drug made by Astra Zeneca, is a powerful … Continue reading Boosting Mesothelioma Survival with VEGF-Inhibitor »

Length of Time Between Surgeries a Marker for Mesothelioma Survival

Peritoneal mesothelioma patients who survive more than two years after surgery are the ones most likely to benefit from a second surgery if their cancer recurs. That is the conclusion of cancer researchers at the City of Hope Cancer Center and Wake Forest School of Medicine in an article newly published in the Journal of Surgical Oncology. Using a City of Hope database of 1,314 … Continue reading Length of Time Between Surgeries a Marker for Mesothelioma Survival »

Cholesterol Drug May Protect Mesothelioma Patients from Radiation

A new study suggests that the cholesterol-lowering drug pravastatin could one-day be used to help protect mesothelioma patients from the damaging side effects of radiotherapy. According to Japanese researchers, mice with malignant mesothelioma who were given pravastatin (Pravachol) in drinking water prior to receiving radiation experienced less damage to healthy cells in their lungs and intestines. The results suggest that pravastatin might make radiotherapy safer … Continue reading Cholesterol Drug May Protect Mesothelioma Patients from Radiation »

Standardization Needed for Peritoneal Mesothelioma Treatment

Mesothelioma researchers in Belgium and the US have some good news and some bad news about peritoneal mesothelioma treatment. The good news is that the combination of cytoreductive surgery to remove the mesothelioma tumor and intraperitoneal chemotherapy (HIPEC) to kill residual cancer cells improves mesothelioma survival. Overall, the method is so effective that the authors say the combination should now be considered standard of care … Continue reading Standardization Needed for Peritoneal Mesothelioma Treatment »

Immunotherapy and Radiation: A Powerful Mesothelioma Combo

New research suggests that, in the battle against malignant pleural mesothelioma, a treatment combining of immunotherapy drugs with radiotherapy may be a powerful new weapon. Researchers at the University of Pennsylvania reached that conclusion after reviewing the few existing studies on this emerging multimodal mesothelioma treatment for an article in Translational Lung Cancer Research.   Current available treatments for pleural mesothelioma, an aggressive lung-related cancer,  include surgical resection, … Continue reading Immunotherapy and Radiation: A Powerful Mesothelioma Combo »

Predicting Mesothelioma Outcomes with Soluble Mesothelin

New research suggests that a protein often used to help diagnose and track malignant mesothelioma may also be a valuable prognostic indicator. Soluble mesothelin-related protein (SMRP) is a biomarker for pleural mesothelioma, an aggressive asbestos-linked cancer that causes few symptoms until in its late stages. The presence of SMRP in the blood indicates that mesothelial cells on the lining around the lungs have been damaged. … Continue reading Predicting Mesothelioma Outcomes with Soluble Mesothelin »

IMRT Beats Conformal Radiotherapy for Pleural Mesothelioma

The targeted radiotherapy technique known as intensity-modulated radiotherapy (IMRT) may offer a safer way to treat pleural mesothelioma tumors with fewer side effects. Researchers at Gazi University in Ankara, Turkey recently compared the outcomes of  twenty-four radiation therapy plannings in patients with malignant pleural mesothelioma and found that IMRT was both less dangerous and more effective. Radiotherapy for Mesothelioma Radiotherapy is often used in pleural … Continue reading IMRT Beats Conformal Radiotherapy for Pleural Mesothelioma »

Get your free copy of
“Surviving Mesothelioma” Today!